A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, 2-Period Crossover Study to Evaluate the Effect of RM-493 on Energy Expenditure in Obese Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus First in man; Pharmacodynamics
- Sponsors Rhythm
- 26 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2013 New trial record